University of Miami Sylvester Comprehensive Cancer Center


 

Improved Outcomes With Ramucirumab & Docetaxel in mNSCLC After Failure of IO: REVEL Trial

344 views
July 15, 2021
Comments 1
Login to view comments. Click here to Login